New cholesterol drug SHR-1918 enters final testing phase

NCT ID NCT07230730

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 3 trial tests whether the experimental drug SHR-1918 can safely lower LDL cholesterol and triglycerides in 900 adults with hyperlipidemia who are already on statins. Participants are randomly assigned to receive SHR-1918 or a placebo. The study aims to see if the drug improves key lipid levels over 24 weeks.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

SHR-1918

What this could lead to

If successful, SHR-1918 could offer a new option to help control high cholesterol and triglycerides in people already taking statins.

What could go wrong

This is a phase 3 trial, but results may not show a meaningful benefit over placebo. Side effects are possible, and the drug may not work for everyone.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HYPERLIPIDEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hyperlipidemia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • The Second Affiliated Hospital Zhejiang University School of Medicine

    RECRUITING

    Hangzhou, Zhejiang, 310009, China

    Contact